Diagnostic solutions for Pharmacists
Take an integrated approach to point-of-care testing
Integrated diagnostic solutions for pharmacists
Empower pharmacists with BD’s integrated diagnostic solutions portfolio, including point-of-care testing capabilities. Portable, convenient analyzers offer rapid results to guide your patients to the appropriate path to care.
.png)
The BD Veritor™ Plus System offers convenient point-of-care testing for SARS-CoV-2*, Influenza A+B, Group A Streptococcus, and respiratory syncytial virus and combines rapid, reliable results with ease of implementation and simple workflow options.
Discover how easy sample collection can simplify testing workflows for reliable results you can act on.
Get in touch with a sales representative
Diagnostic tests classify infections and guide therapies, enabling clinicians to implement effective antimicrobial interventions
-
BD Integrated Diagnostic Solutions aim to optimize patient care pathways through essential tests crucial for making treatment decisions.
-
BD Integrated Diagnostic Solutions are designed to support your ability to minimize the effort needed to get accurate diagnostic results and help keep your lab ahead of the curve.
-
BD diagnostic solutions optimize patient care pathways through essential tests crucial for treatment decisions.
References
References:
- Ngo A, Gandhi P, Miller WG. Frequency that laboratory tests influence medical decisions. J ApplLab Med. 2017;1(4):410-414.
- Hawkins R. Managing the pre- and post-analytical phases of the total testing process. Ann Lab Med. 2012;32:5-16.
Notes:
* The BD Veritor™ System for Rapid Detection of SARS-CoV-2 is intended for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in direct anterior nasal swabs from individuals who are either suspected of COVID-19 by their health care provider within the first five days of the onset of symptoms, or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests. This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories. RSV=respiratory syncytial virus; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated, or authorization is revoked sooner. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
